1 Hypothesis, Multiple Implications: Adenoviral Vector Vaccines and Thrombosis with Thrombocytopenia Syndrome
The RPTH Journal (Research and Practice in Thrombosis and Haemostasis) shared an insightful post on LinkedIn:
”This new study investigates adenoviral vector vaccine-associated thrombosis/thrombocytopenia risk.
- Adenoviral vectors can infect megakaryocytes
- Concurrent infection may increase chemokine receptor expression
Senior Author: Joseph Torresi”
Read the full article here.
In the article ”Adenovirus vectors can infect mouse megakaryocytes – implications for vaccine-induced thrombosis/thrombocytopenia” by Simon Collett, Joseph Torresi et al. in the RPTH Journal, a potential role of adenoviral vector vaccines in inducing TTS is discussed.
Adenoviruses, adenoviral vector-based vaccines, and gene delivery systems have been associated with thrombosis with thrombocytopenia syndrome (TTS), a rare but serious complication.
The precise mechanisms underlying this condition remain unclear.
It was previously hypothesized that megakaryocytes (MKs)—the precursor cells responsible for platelet production—play a central role in the development of adenovirus- or vector-induced TTS.
Emerging evidence supports the notion that MKs are a heterogeneous population, including subsets with distinct immune-related functions.
This study demonstrates that adenoviral infection preferentially targets higher-ploidy CD41⁺CD42⁺ MKs and those expressing high levels of CXCR4 (CXCR4^hi).
These findings implicate specific MK subsets and surface receptors in the cellular response to adenoviral exposure and provide a potential mechanistic link to thrombocytopenia and thrombotic events observed post-vaccination or gene therapy.
Find all the latest scientific advancements in the World of Thrombosis posted in Hemostasis Today.
-
Jul 26, 2025, 18:32From Jawless Fish to Mammals: Clotting Cascade Origins
-
Jul 26, 2025, 15:12ISTH 2025 Guidelines: Submit Your Topic Proposals by September 8
-
Jul 26, 2025, 15:05Beyond the Needle: The BUTTERFLY Study Eases LMWH Burden
-
Jul 26, 2025, 14:58Join ATHN's Glanzmann Thrombasthenia Research: Help Advance Bleeding Disorder Care
-
Jul 26, 2025, 13:16Dr. William Aird on Diagnosing ITP: Key Clinical Clues
-
Jul 26, 2025, 18:21C-Terminal VWF Variants in von Willebrand Disease: Functional Insights from the D4-C6 Domains
-
Jul 26, 2025, 17:271 Hypothesis, Multiple Implications: Adenoviral Vector Vaccines and Thrombosis with Thrombocytopenia Syndrome
-
Jul 25, 2025, 05:40Why Is Gene Therapy Uptake in Hemophilia Slower Than Expected
-
Jul 25, 2025, 05:27New Insights: Diagnosing Pulmonary Embolism in COPD Patients
-
Jul 25, 2025, 05:11Global Study Sheds Light on Low-Dose Prophylaxis in Hemophilia A
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 26, 2025, 16:14Cesar Garrido: Forging Strong Partnerships on WHA78 ''Global Health Equity'' Event
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders
-
Jul 23, 2025, 10:43From Blood Clot Survivor to NFL History: Trey Smith’s Record Deal
-
Jul 22, 2025, 16:48How Children See Blood Clots: World Thrombosis Day Shares Artwork from Young Artists